Anavex Life Sciences Corp (AVXL)
4.195
+0.08
(+1.82%)
USD |
NASDAQ |
Jul 05, 16:00
4.195
0.00 (0.00%)
After-Hours: 17:19
Anavex Life Sciences SG&A Expense (TTM): 11.24M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 11.24M |
December 31, 2023 | 11.33M |
September 30, 2023 | 12.04M |
June 30, 2023 | 13.35M |
March 31, 2023 | 13.29M |
December 31, 2022 | 13.32M |
September 30, 2022 | 13.07M |
June 30, 2022 | 12.05M |
March 31, 2022 | 11.30M |
December 31, 2021 | 10.61M |
September 30, 2021 | 9.018M |
June 30, 2021 | 7.542M |
March 31, 2021 | 6.489M |
December 31, 2020 | 5.975M |
September 30, 2020 | 5.857M |
June 30, 2020 | 6.089M |
March 31, 2020 | 6.096M |
December 31, 2019 | 6.437M |
September 30, 2019 | 6.847M |
June 30, 2019 | 6.693M |
March 31, 2019 | 6.924M |
December 31, 2018 | 6.353M |
September 30, 2018 | 5.989M |
June 30, 2018 | 5.869M |
March 31, 2018 | 5.653M |
Date | Value |
---|---|
December 31, 2017 | 5.280M |
September 30, 2017 | 5.008M |
June 30, 2017 | 6.864M |
March 31, 2017 | 6.594M |
December 31, 2016 | 6.568M |
September 30, 2016 | 8.810M |
June 30, 2016 | 8.814M |
March 31, 2016 | 8.392M |
December 31, 2015 | 7.754M |
September 30, 2015 | 4.837M |
June 30, 2015 | 1.912M |
March 31, 2015 | 1.932M |
December 31, 2014 | 2.384M |
September 30, 2014 | 2.237M |
June 30, 2014 | 3.312M |
March 31, 2014 | 2.666M |
December 31, 2013 | 1.889M |
September 30, 2013 | 1.873M |
June 30, 2013 | 1.029M |
March 31, 2013 | 1.244M |
December 31, 2012 | 1.482M |
September 30, 2012 | 1.663M |
June 30, 2012 | 1.767M |
March 31, 2012 | 2.321M |
December 31, 2011 | 3.172M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
5.857M
Minimum
Sep 2020
13.35M
Maximum
Jun 2023
9.576M
Average
10.61M
Median
Dec 2021
SG&A Expense (TTM) Benchmarks
Ventyx Biosciences Inc | 33.13M |
Checkpoint Therapeutics Inc | 8.844M |
Biogen Inc | 2.526B |
Amicus Therapeutics Inc | 289.34M |
InfuSystems Holdings Inc | 59.82M |